Blackstone's Sweetened Bid Gets Backing of Warehouse REIT Board
Blackstone's latest offer is 'fair and reasonable,' Warehouse REIT said in a statement Friday. The revised proposal provides shareholders with a 'certain all-cash offer' at a premium to Tritax's cash and share bid, Warehouse REIT chairman Neil Kirton said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Investing in Eastern & Oriental Berhad (KLSE:E&O) five years ago would have delivered you a 132% gain
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. For example, the Eastern & Oriental Berhad (KLSE:E&O) share price has soared 124% in the last half decade. Most would be very happy with that. It's also good to see the share price up 12% over the last quarter. But this could be related to the strong market, which is up 4.8% in the last three months. Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the last half decade, Eastern & Oriental Berhad became profitable. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here. Given that the company made a profit three years ago, but not five years ago, it is worth looking at the share price returns over the last three years, too. We can see that the Eastern & Oriental Berhad share price is up 88% in the last three years. Meanwhile, EPS is up 15% per year. Notably, the EPS growth has been slower than the annualised share price gain of 24% over three years. So one can reasonably conclude the market is more enthusiastic about the stock than it was three years ago. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here. We'd be remiss not to mention the difference between Eastern & Oriental Berhad's total shareholder return (TSR) and its share price return. Arguably the TSR is a more complete return calculation because it accounts for the value of dividends (as if they were reinvested), along with the hypothetical value of any discounted capital that have been offered to shareholders. Its history of dividend payouts mean that Eastern & Oriental Berhad's TSR of 132% over the last 5 years is better than the share price return. We regret to report that Eastern & Oriental Berhad shareholders are down 12% for the year. Unfortunately, that's worse than the broader market decline of 6.8%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 18% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should learn about the 2 warning signs we've spotted with Eastern & Oriental Berhad (including 1 which makes us a bit uncomfortable) . But note: Eastern & Oriental Berhad may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Malaysian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Bloomberg
42 minutes ago
- Bloomberg
UK Doesn't Know How Much Billionaires Pay in Taxes, MPs Say
The UK tax authority cannot identify how much tax the nation's billionaires pay on their wealth, hampering its ability to properly impose levies on the ultra-wealthy, according to lawmakers. His Majesty's Revenue and Customs has an incomplete grasp of the financial affairs of billionaires, the cross-party group of Members of Parliament on the Public Accounts Committee said in a report Wednesday, expressing disappointment over the lack of data collection on their wealth and assets.
Yahoo
an hour ago
- Yahoo
Retirement Ready: 3 Dividend Stocks to Set and Forget
A retirement-ready portfolio consists of reliable, income-generating stocks that quietly compound over time. Realty Income (O), Verizon Communications (VZ), and Pfizer (PFE) are all solid dividend stocks designed for long-term wealth. These are stocks that provide a strong balance of stability, income, and growth. Seeking Passive Income? This 'Strong Buy' Dividend Stock Yields 8.6%. Forget Chasing Yields: These 3 Dividend Stocks Are Built to Last Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Few dividend stocks can match Realty Income's (O) long-term resilience, consistent dividend growth, and dependable cash flow. The company's most appealing feature for retirement investors is its consistent and growing monthly dividend, which is supported by long-term rental income from a well-diversified portfolio. Realty Income has been paying dividends for 661 consecutive months. It has increased its dividend for more than 30 years in a row, earning the title of Dividend Aristocrat. Unlike most companies that pay quarterly dividends, Realty Income pays monthly dividends, a unique feature that perfectly fits retirees' regular income requirements. It provides an attractive yield of 5.64%, which is higher than the real estate sector's average of 4.46%. Known as The Monthly Dividend Company, it is a real estate investment trust (REIT) that owns and manages a large portfolio of commercial properties leased to high-quality tenants under long-term net lease agreements. These leases are typically longer than nine years and are structured as 'triple net leases,' which means the tenant is responsible for property taxes, insurance, and maintenance, reducing cost volatility for Realty Income and increasing predictable cash flows. Adjusted funds from operations (AFFO) is the primary earnings metric for REITs. It reflects actual, recurring cash available to pay out for dividends. While its forward AFFO dividend payout ratio is high at 75.4%, the company has seen consistent AFFO per share growth in recent years. Overall, Wall Street has rated Realty Income stock a 'Moderate Buy.' Of the 23 analysts that cover the stock, five recommend a 'Strong Buy,' one rates it a 'Moderate Buy,' and 17 say it is a 'Hold.' The mean target price for the stock is $60.97, which is 5% above current levels. The Street-high estimate of $68 implies upside of 19% over the next 12 months. Verizon Communications (VZ) is one of the largest telecommunications companies in the U.S. Its revenue comes primarily from wireless service plans, data usage, and broadband subscriptions. These are recurring revenues that are not impacted by cyclical fluctuations. This allows the company to pay out generous and consistent dividends. The company pays an attractive dividend yield of around 6.5%. In addition, it has increased its dividend for the past 20 years. Unlike some high-yield stocks that are volatile, Verizon's dividend is supported by consistent free cash flow generated by a customer base that continues to renew its mobile and broadband services. Verizon maintains a reasonable dividend payout ratio of 56% of earnings, allowing for continued reinvestment in the business and potential hikes. Overall, on Wall Street, Verizon stock is rated a 'Moderate Buy.' Out of the 28 analysts who cover Verizon stock, nine rate it a 'Strong Buy,' three suggest it's a 'Moderate Buy,' and 16 rate it a "Hold.' Its average price target of $47.70 suggests that the stock can increase by 15% over current levels. However, its high target price of $58 implies upside potential of 40% over the next 12 months. Pfizer (PFE), valued at $146.6 billion, is one of the world's largest pharmaceutical companies. While Pfizer is well-known for its COVID-19 vaccine, its portfolio includes essential medications and vaccines in oncology, cardiology, immunology, endocrinology, and neurology. With hundreds of millions of people relying on its therapies, Pfizer generates consistent revenue across economic cycles, allowing it to pay consistent dividends. Adjusted earnings increased by a staggering 69% in 2024. Even as COVID-19-related revenues return to earth, Pfizer's long-term outlook remains positive, thanks to a robust pipeline of candidates, many of which are in late-stage development. Some of its most well-known products include Eliquis (a blood thinner), the Vyndaqel family of treatments, and Ibrance (oncology), all of which generated significant revenue in the most recent first quarter of 2025. Pfizer's dividend yield hovers around 6.7%, which is significantly higher than the healthcare sector average of 1.6%. Additionally, its forward payout ratio is a manageable 55.7%, allowing for future increases and financial flexibility. Despite near-term headwinds, the company has consistently increased its dividend over the last 16 years, making it a reliable dividend stock. On Wall Street, overall, Pfizer stock is rated a 'Moderate Buy.' Out of the 22 analysts who cover PFE stock, six rate it a 'Strong Buy,' one rates it a 'Moderate Buy,' 14 say it is a 'Hold,' and one suggests a 'Strong Sell.' Its average price target of $27.71 suggests that the stock can increase by 8% over current levels. However, its high target price of $33 implies upside potential of 32% over the next 12 months. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
